What is wrong with orphan drug policies? suggestions for ways forward

Value in Health

Volumn 15, Issue 8, 2012, Pages 1182-1184

  Kanavos, Panos ^a   Nicod, Elena ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

access to health care; orphan drugs; pricing and value assessment; rare diseases; regulatory

Indexed keywords

ORPHAN DRUG;

ARTICLE; DRUG COST; DRUG INDICATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE;

COSTS AND COST ANALYSIS; DRUG INDUSTRY; EUROPE; HEALTH SERVICES ACCESSIBILITY; HUMANS; ORPHAN DRUG PRODUCTION; POLICY;

EID: 84871205095     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.08.2202     Document Type: Article

References (21)

1. A. Cote, and B. Keating What is wrong with orphan drug policies? Value Health 15 2012 1184 1190
2. K. Charmaz Grounded theory: life history and postmodern challenge N. Denzin, Y. Lincoln, Strategies of Qualitative Inquiry 2nd ed 2003 Sage Thousand Oaks, CA 249 291
3. G. Gatta, J.M. Van der Zwan, and P. Casali Rare cancers are not so rare: the rare cancer burden in Europe Eur J Cancer 47 2011 2493 2511
4. European Organisation for Rare Diseases Rare Diseases: Understanding This Public Health Priority 2005 European Organisation for Rare Diseases Paris
5. R. Sullivan, G. McVie, G. Lewison, and P. Kanavos Public-private partnership in cancer drug development: a policy analysis Ann Oncol 21 2010 168 169
6. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clinic 61 2011 133 134
7. P. Farmer, J. Frenk, and F.M. Knaul Expansion of cancer care and control in countries of low and middle income: a call to action Lancet 376 2010 1186 1193
8. M.F. Drummond, D.A. Wilson, and P. Kanavos Assessing the economic challenges posed by orphan drugs Int J Technol Assess Health Care 23 2007 36 42 (Pubitemid 46648298)
9. S. Simoens Pricing and reimbursement of orphan drugs: the need for more transparency Orphanet J Rare Diseas 6 2011 1 8
10. C. McCabe, T. Stafinski, and D. Menon Is it time to revisit orphan drug policies? BMJ 341 2010 c4777
11. Burden of Disease and Quality of Life - Rare Diseases (BURQOL-RD). Social economic burden and health-related quality of life in patients with rare diseases in Europe (BURQOL-RD) - Leaflet. August 2012. http://www.burqol-rd.com/ doc/BURQOL-Leaflet-1.pdf. [Accessed August 8, 2012].
12. Aymé S, Rodwell C, eds. 2011 Report on the state of the art of rare disease activities in Europe of the EUCERD: Part II - European Commission and other European activities. European Union Committee of Experts on Rare Diseases (EUCERD), Brussels, July 2011. http://www.eucerd.eu/upload/file/ Reports/2011ReportStateofArtRDActivitiesII.pdf. [Accessed August 17, 2012].
13. Ministry of Health, Health Products and Food Branch. Guidance Document: Notice of Compliance with Conditions (NOC/c). Ottawa, Canada: Health Canada, June 2011.
14. J. Lexchin, and B. Mintzes Medicine reimbursement recommendations in Canada, Australia, and Scotland Am J Manag Care 14 2008 581 588
15. Committee for Medicinal Products for Human Use (CHMP). Guidelines of the Scientific Application and the Practical Arrangements Necessary to Implement Commission Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of the Regulations No 726/2004. London: European Medicines Agency, December 2006.
16. M.E. Haffner, J. Torrent-Farnell, and P.D. Maher Does orphan drug legislation really answer the needs of patients? Lancet 371 2008 2041 2044 (Pubitemid 351818196)
17. C. McCabe, K. Claxton, and A. Tsuchiya Orphan drugs and the NHS: should we value rarity? BMJ 331 2005 1016 1019 (Pubitemid 41552456)
18. A. Denis, L. Mergaert, and C. Fostier A comparative study of European rare disease and orphan drug markets Health Policy 97 2010 173 179
19. A. Denis, L. Mergaert, and C. Fostier Issues surrounding orphan disease and orphan drug policies in Europe App Health Econ Health Policy 8 2010 343 350
20. Commission of the European Communities. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000;L18:1-5.
21. P. Casali The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO) Ann Oncol 18 2007 1923 1925 (Pubitemid 350286226)